retatrutide logo Geno X A pharmacy label for Platinum

The answer lies in its mechanism

Roughly 45% of large employers now include at least one anti-obesity medication on their formulary, up from about 25% in 2023

In the future, Retatrutide may be considered for individuals who meet specific health criteria, such as those living with obesity or weight-related conditions, but suitability would depend on personal medical factors

If youre weighing headline offers, look for structured deals that reward steady play rather than single bursts

For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred

Obesity 17 , 17361743 (2009)